Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 738

1.

Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells.

Dicker F, Kater AP, Fukuda T, Kipps TJ.

Blood. 2005 Apr 15;105(8):3193-8. Epub 2004 Aug 31.

2.
3.

Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.

Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps TJ.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3854-9. Epub 2002 Mar 12.

4.

Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

Song JH, Bellail A, Tse MC, Yong VW, Hao C.

J Neurosci. 2006 Mar 22;26(12):3299-308. Erratum in: J Neurosci. 2006 May 3;26(18):4983.

6.
7.

TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.

Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama-Okazaki T, Suzuki T, Sugita K, Nakazawa S.

Blood. 2003 May 1;101(9):3658-67. Epub 2002 Dec 27.

8.

Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.

Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P, Fanin R, Zauli G.

J Cell Physiol. 2005 Nov;205(2):246-52.

PMID:
15887227
9.

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM.

Oncogene. 2002 Oct 3;21(44):6809-18.

10.
11.

Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.

Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM, Kuschak B, Begleiter A, Gibson SB.

Oncogene. 2003 Nov 13;22(51):8356-69.

PMID:
14614459
13.

CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily.

Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, Young LS.

Mol Cell Biol. 2000 Aug;20(15):5503-15.

14.

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.

Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T.

Oncogene. 2004 Aug 19;23(37):6261-71.

PMID:
15208660
15.
17.

CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.

Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, van Lier RA, van Oers MH, Eldering E.

Br J Haematol. 2004 Nov;127(4):404-15.

PMID:
15521917
18.

TRAIL/Apo-2 ligand induces primary plasma cell apoptosis.

Ursini-Siegel J, Zhang W, Altmeyer A, Hatada EN, Do RK, Yagita H, Chen-Kiang S.

J Immunol. 2002 Nov 15;169(10):5505-13.

19.

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM.

Cell Death Differ. 2004 Dec;11 Suppl 2:S193-206.

20.

Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.

Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG.

Gynecol Oncol. 2005 Mar;96(3):705-13.

PMID:
15721415

Supplemental Content

Support Center